Shivalik Rasayan Limited reported a 12% decline in consolidated net profit to ₹1,796.88 lakh for the financial year ended March 31, 2026, compared to ₹2,042.26 lakh in the previous year. Revenue from operations for the consolidated entity increased 18% to ₹36,800.32 lakh from ₹31,177.31 lakh in FY25. The board approved the audited financial results and recommended a final dividend of 50 paise per equity share, subject to shareholder approval.

For the quarter ended March 31, 2026, the company reported a consolidated net profit of ₹717.32 lakh, a rise from ₹519.06 lakh in the corresponding quarter of the previous year. Total revenue for the quarter stood at ₹10,473.21 lakh. The statutory auditors, M/s Rahul Chaudhary & Associates, issued an unmodified opinion on the financial results.

Financial Performance

The standalone net profit for FY26 stood at ₹817.25 lakh, a decrease from ₹1,386.68 lakh in the previous year. Standalone revenue from operations for the year was ₹17,023.35 lakh, up from ₹14,922.59 lakh in FY25. The company operates across three business segments: Agro Chemical, Pharma API, and Pharma Formulations. The consolidated results include the financials of its associate, Medicamen Biotech Limited.

Board Decisions

The board approved the appointment of M/s Arun Agarwal & Co. as the Internal Auditor for FY27, following the resignation of M/s Amar Sharma & Co. Cheena & Associates were appointed as the Cost Auditor for FY27. The board accepted the resignation of Mr. Sanjay Bansal as a Non-Executive Director and reconstituted the Audit Committee, Stakeholders Relationship Committee, Nomination and Remuneration Committee, and Risk Management Committee effective May 27, 2026.

Shivalik Rasayan Limited announced that Non-Executive Director Sanjay Bansal has resigned from the board effective May 27, 2026. The resignation was submitted due to personal reasons and has been accepted by the management from the close of business hours on the same day. The company confirmed there are no material reasons for the departure other than those stated in the resignation letter.

Bansal served on several key committees during his tenure, including the Audit Committee, Stakeholders Relationship Committee, Nomination and Remuneration Committee, and Risk Management Committee. His departure necessitates statutory filings and formalities under applicable laws and SEBI Listing Regulations.

The disclosure was made to BSE Limited and the National Stock Exchange of India Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015. The company stated that the information is also available on its website.

Director Details

Committee Memberships

Bansal held membership in the following committees:

• Audit Committee
• Stakeholders Relationship Committee
• Nomination and Remuneration Committee
• Risk Management Committee

Additionally, Bansal held a position as a Non-Executive Director at Medicamen Biotech Limited.